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OBJECTIVES This study was designed to compare the cost-effectiveness of implantable cardioverter-
defibrillator (ICD) placement with and without risk stratification with microvolt T-wave
alternans (MTWA) testing in the MADIT-II (Second Multicenter Automatic Defibrillator
Implantation Trial) eligible population.
BACKGROUND Implantable cardioverter-defibrillators have been shown to prevent mortality in the
MADIT-II population. Microvolt T-wave alternans testing has been shown to be effective in
risk stratifying MADIT-II–eligible patients.
METHODS On the basis of published data, cost-effectiveness of three therapeutic strategies in MADIT-
II–eligible patients was assessed using a Markov model: 1) ICD placement in all; 2) ICD
placement in patients testing MTWA non-negative;, and 3) medical management. Outcomes
of expected cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness
were determined for patient lifetime.
RESULTS Under base-case assumptions, providing ICDs only to those who test MTWA non-negative
produced a gain of 1.14 QALYs at an incremental cost of $55,700 when compared to medical
therapy, resulting in an incremental cost-effectiveness ratio (ICER) of $48,700/QALY.
When compared with a MTWA risk-stratification strategy, placing ICDs in all patients
resulted in an ICER of $88,700/QALY. Most (83%) of the potential benefit was achieved by
implanting ICDs in the 67% of patients who tested MTWA non-negative. Results were most
sensitive to the effectiveness of MTWA as a risk-stratification tool, MTWA negative screen
rate, cost and efficacy of ICD therapy, and patient risk for arrhythmic death.
CONCLUSIONS Risk stratification with MTWA testing in MADIT-II–eligible patients improves the
cost-effectiveness of ICDs. Implanting defibrillators in all MADIT-II–eligible patients,
however, is not cost-effective, with one-third of patients deriving little additional benefit at
great expense. (J Am Coll Cardiol 2006;48:112–21) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.051Cardiology Foundation
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audden cardiac death (SCD) from ventricular arrhythmias
emains a leading cause of death in patients with ischemic
eart disease and left ventricular dysfunction (1). Although
ntiarrhythmic drug therapy has proved disappointing, re-
ent clinical trials have demonstrated that implantable
ardioverter-defibrillators (ICDs) reduce SCD mortality in
his high-risk population (2–5). Furthermore, the
ADIT-II (Second Multicenter Automatic Defibrillator
mplantation Trial) showed that invasive electrophysiologic
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hio; and Columbia University Medical Center, New York, New York. Dr. Chan is
upported by a National Institutes of Health Cardiovascular Multidisciplinary
esearch Training Grant and by the Ruth L. Kirchstein Research Service Award.
either sponsor had any involvement in the design, collection, management, or
nalysis of the study or in manuscript preparation.e
Manuscript received November 2, 2005; revised manuscript received January 31,
006, accepted February 7, 2006.esting was not a prerequisite for these high-risk patients to
eceive benefit from ICDs (3).
Prior cost-effectiveness analyses from clinical trials with
CDs have shown variability in cost-effectiveness estimates
6–8), with the MADIT-I study, which limited ICD
mplantation to those at high risk based on electrophysi-
logic testing, showing the most favorable cost-effectiveness
stimate ($27,000 per quality-adjusted life-year [QALY]
ained). A recent analysis in MADIT-II–eligible patients
odeled for patient lifetime showed that ICDs had an
ncremental cost-effectiveness ratio of $57,300 per QALY
ompared to medical therapy (9). Nonetheless, therapies
hat may be deemed cost-effective may remain unaffordable
o society if the therapy of interest is expensive and the
isease prevalence high.
Recently, the Centers for Medicare and Medicaid Ser-
ices (CMS) expanded ICD coverage to MADIT-II–
ligible patients despite ongoing concerns regarding cost
nd cost-effectiveness (10). Effective risk-stratification strat-
gies in the MADIT-II–eligible population to determine
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July 4, 2006:112–21 Cost-Effectiveness of MTWA Screeninghich patients derive the largest benefit would improve the
ost-effectiveness of ICD therapy (8). Microvolt T-wave alter-
ans (MTWA) testing has been shown to be effective in
isk-stratifying MADIT-II–eligible patients (11–13). One
tudy of 129 MADIT-II–eligible patients derived from two
rospective cohorts found a 2-year arrhythmic event rate of
.0% in patients who tested MTWA negative and 15.6% in
atients who tested MTWA non-negative (positive and
ndeterminate) (11). Another recent study of 177 MADIT-
I–eligible patients found a 2-year mortality rate of 3.8% in
atients who tested MTWA negative and 17.8% in patients
ho tested MTWA non-negative (12). In the largest study
o date involving 537 MADIT-II–eligible patients, a non-
egative MTWA test was associated with a greater than
wo-fold increased risk of all-cause mortality, even after
igure 1. Simplified schematic of Markov model. The square node at the f
ardioverter-defibrillators (ICDs) for all, medical therapy, or risk stratificati
vents, and M represents the Markov process with multiple health states (
ption. Patients who survive ICD implantation or who are on medical thera
hich includes all potential clinical outcomes that occur with each cycle. Pa
Abbreviations and Acronyms
CMS  Centers for Medicare and Medicaid
Services
ICD  implantable cardioverter-defibrillator
ICER  incremental cost-effectiveness ratio
MADIT-II  Second Multicenter Automatic
Defibrillator Implantation Trial
MTWA  microvolt T-wave alternans
QALY  quality-adjusted life-year
SCD  sudden cardiac deatho cardiac arrests prevented by defibrillator therapy. Patients in the MTWA risk
trategy if they test MTWA non-negative and the medical therapy strategy if tdjusting for age, left ventricular ejection fraction, a QRS
120 ms on electrocardiogram, clinical variables, and med-
cation treatment (13).
Given the discriminating power of MTWA testing in
isk-stratifying MADIT-II–eligible patients, we evaluated
he cost-effectiveness of ICD therapy with and without risk
tratification with MTWA compared to medical therapy
lone using a decision-analytic model.
ETHODS
odel design. We used a Markov decision analysis model
o evaluate three treatment strategies for a hypothetical
5-year-old cohort with ischemic heart disease and left
entricular ejection fraction 30% (Fig. 1) (14). Taking a
ocietal perspective (which includes not only direct medical
osts but also accounts for costs and lost productivity from
isability) (14), our model tracked short- and long-term
utcomes, adverse events (e.g., lead fracture and lead infec-
ion with ICD therapy, disability after surviving nondefi-
rillator resuscitation of cardiac arrest), and the resultant
osts and utilities for each treatment strategy. For the
ohort, we simulated outcomes with each treatment strategy
nd followed patients until death.
arget population and model strategies. Three treatment
trategies were evaluated in a hypothetical 65-year-old
ohort of MADIT-II–eligible patients with ischemic heart
t symbolizes the choice between the three treatment strategies: implantable
th microvolt T-wave alternans (MTWA) testing. Circles represent chance
ildly disabled, moderately disabled, severely disabled) for each treatment
er the Markov tree (denoted by two circles and arrow within a rectangle),
in the medical therapy arm are not subject to ICD complications and havear lef
on wi
well, m
py ent
tientsstratification strategy enter the same pathway as those in the ICD-for-all
hey test MTWA negative.
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Cost-Effectiveness of MTWA Screening July 4, 2006:112–21Table 1. Model Variables
Input Variables
Base-Case Value
(Range for Sensitivity Analysis) Source (Reference)
Mortality
Medical therapy, %/yr 11–13,30
Total 10.1 (7.0–13.0)
SCD 5.2 (3.6–6.6)
Non-SCD 4.9 (3.4–6.4)
ICD therapy, %/yr
Total 6.9 (4.8–8.9)
SCD 2.0 (1.4–2.5)
Non-SCD 4.9 (3.4–6.4)
MTWA risk stratification 11–13,30
Non-negative, %/yr
Total 12.5 (8.7–16.3)
SCD
Baseline 6.4 (4.5–8.3)
With ICD therapy 2.4 (1.7–3.2)
Non-SCD 6.1 (3.3–7.2)
MTWA negative, %/yr
Total 5.3 (3.7–6.9)
SCD 2.7 (1.9–3.5)
Non-SCD 2.6 (1.8–3.4)
Resuscitation
Initial resuscitation rate, % 10 (5–30) 16–18
Survive to hospital discharge, % 15 (3–30) 17–20
Post-discharge survival status 21
No disability, % 75 (50–95)
Moderate disability, % 15 (5–30)
Severe disability, % 10 (0–20)
Annual mortality rate, % 21–24
No disability 11 (7–16)
Moderate disability 18 (15–20)
Severe disability 30 (20–40)
ICD complications
Procedural mortality, % 0.3 (0.0–0.9) 3,26,27
Lead failure, %/yr 3.0 (1.0–5.0) 29,31,38
Lead infection, %/yr 1.0 (0.5–2.0) 25,28,29,31,38
MTWA
Unable to screen, % 15 (10–20) 3, estimate
Able to screen, %
MTWA negative 33 (20–40) 11–13,30
MTWA non-negative 67 (60–80) 11–13,30
Costs of care (2004 U.S. $)
Single event
ICD
Initial implantation 35,000 (30,000–50,000) 7,29,31,32
Generator replacement (every 6 yrs) 18,000 (12,000–24,000) 29,32
Lead failure 7,000 (5,000–9,000) 32
Lead infection 51,700 (35,000–70,000) 25,32
Death
Non-arrest 9,000 (0–18,000) 34,35
Cardiac arrest
Survived until discharge 24,800 (11,300–46,100) 33
Died before discharge 12,900 (2800–23,600) 33
Annual care
MTWA screening 400 (300–500) Cost-accounting
No history of cardiac arrest 10,600 (7,000–20,000) 31,32
Survived cardiac arrest 7,33,36
No disability 18,000 (15,000–21,000)
Moderate disability 22,000 (19,000–25,000)
Severe disability 30,000 (20,000–40,000)
Continued on next page
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July 4, 2006:112–21 Cost-Effectiveness of MTWA Screeningisease and left ventricular dysfunction (ejection fraction
30%). Patients who met MADIT-II trial exclusion crite-
ia were excluded from the cohort. The strategies were:
. Medical therapy, as in the MADIT-II trial.
. ICDs for all.
. Risk stratification with MTWA. Given that positive
and indeterminate MTWA tests have similar prognostic
utility in predicting mortality among patients with
ischemic cardiomyopathy (13), we modeled those who
would test MTWA non-negative (positive and indeter-
minate) to receive ICDs and those who would test
MTWA negative to receive medical therapy only.
For the analyses, TreeAge Pro (Williamstown, Massa-
husetts) was used to design the model. The cycle length
as three months, the time horizon was lifetime, and costs
nd utilities were discounted at an annual rate of 3%.
robabilities and rates. Base-case values, ranges of the
stimates, and literature sources for our model variables are
hown in Table 1.
ORTALITY RISK. Studies involving MTWA testing in
ADIT-II–eligible patients show two-year mortality rates
f about 11% to 20% (11–13). For the purposes of this
tudy, we used the survival probability derived from Kaplan-
eier estimates from the largest study of MTWA (n 
68) in patients with ischemic cardiomyopathy by Chow et
l. (13). In this study, the three-year survival probability rate
ith medical therapy was similar to that found in the
ADIT-II trial (72.7% for MTWA study and 73.5% for
ADIT-II trial) (T. Chow, personal communication, Oc-
ober 2005). Based on this 3-year survival probability,
nnual mortality rates were modeled to be 10.1%.
In the study by Chow et al. (13), 33% of patients tested
TWA negative, and the age-adjusted mortality hazard
atio was 2.35 for MADIT-II–eligible patients who tested
TWA non-negative relative to those who tested MTWA
egative. Based on the annual mortality rate of 10.1%, a
3% rate of a MTWA negative test, and a hazard ratio of
.35, patients who test MTWA negative and non-negative
ere modeled to have annual mortality rates of 5.3% and
2.5%, respectively.
Analysis of mortality from the MADIT-II trial showed
Table 1. Continued
Input Variables
B
(Range f
Utilities for health states
No history of cardiac arrest
History of cardiac arrest
No disability
Moderate disability
Severe disability
Discount rate, %
Base-case values with the range of estimates for all variables in
that are not one-time events are converted to a 3-month cyc
ICD  implantable cardioverter-defibrillator; MTWA hat 51% of the medical therapy group deaths were from nCD, and the rate of SCD was reduced by 62% in those
mplanted with ICDs (1). This translates into a 31.6%
ll-cause mortality risk reduction for the model (actual
elative mortality reduction from MADIT-II trial  31%).
e assumed the benefit of ICD therapy was constant
ver time, applied these rates to the base-case analysis,
nd explored different rates of SCD death and ICD
fficacy in reducing SCD mortality in sensitivity analysis.
e also age-adjusted annual mortality rates for the
ohort using life tables from the National Center for
ealth Statistics (15).
Individuals with an SCD not prevented by ICD therapy
n each treatment strategy may receive cardiopulmonary
esuscitation in the field. On the basis of published
eports, initial resuscitation rates of 10% in the field and
urvival rates of 15% to hospital discharge were used, for
n overall rate of surviving a cardiac arrest not prevented
y an ICD of 1.5% (16–20). Moreover, the annual
ortality rates of surviving SCD unimpaired, moderately
mpaired (could live independently), and severely im-
aired (required institutionalization) were modeled (21–
4), and all SCD survivors without severe impairment
ho did not already have an ICD implanted were
ssumed to receive one.
OMPLICATIONS OF ICD THERAPY. On the basis of pub-
ished reports, a procedural mortality risk of 0.3% for ICD
mplantation, as well as a 3% annual risk for lead fracture
nd a 1% annual risk for lead infection (with one-half
equiring new endocardial systems), were used for the model
3,25–28). Generator replacements were estimated to occur
very six years, with a range of four to eight years for
ensitivity analysis (29).
TWA TESTING. Because 8% to 9% of patients in the
ADIT-II trial were in atrial fibrillation (3), and because a
mall percentage of MADIT-II–eligible patients are not
ble to perform the short duration of exercise required for
he MTWA screening test, we estimated that 15% of the
nselected MADIT-II population could not be assessed
ith MTWA testing and would therefore receive an ICD in
ur model. Among those able to be tested, prior studies
ave consistently shown that 27% to 35% will test MTWA
ase Value
nsitivity Analysis) Source (Reference)
0.7–1.0) 8,31,38,39
40–44
0.7–1.0)
0.34–0.54)
0.08–0.28)
) 14
arkov model analysis. All variables (rates, costs, and utilities)
for model input by the formula: [(1  rate)(1/#cycles)  1].
volt T-wave alternans; SCD  sudden cardiac death.ase-C
or Se
0.88 (
0.85 (
0.44 (
0.18 (
3 (0–5
the Megative (11–13,30). For our model, we used the estimate of
3
b
u
1
C
i
(
r
l
p
f
c
e
a
t
c
p
(
t
m
w
n
S
d
e
t
w
a
U
w
p
i
e
b
(
w
v
S
f
f
M
t
e
w
w
f
m
1
s
v
t
m
y
e
t
W
s
v
s
R
T
s
I
l
m
a
r
t
M
t
$
g
I
F
a
a
$
t
t
i
i
O
s
s
C
I
o
T
P
R
M
I
t
r
I
116 Chan et al. JACC Vol. 48, No. 1, 2006
Cost-Effectiveness of MTWA Screening July 4, 2006:112–213% from the largest cohort study for the baseline proba-
ility of testing MTWA negative (13), or 28.7% of the
nselected MADIT-II population (after accounting for the
5% unable to perform the test) (13).
osts. Our model assessed discounted costs (3% annually)
n 2004 U.S. dollars from a societal perspective (Table 1)
14). To estimate costs of treatment strategies, Medicare
eimbursement rates, inflation-adjusted values from pub-
ished data, and hospital cost accounting were used (14). All
atients had annual costs of $10,600 related to their heart
ailure and ischemic heart disease (29,31,32). Initial ICD
osts utilized inputs from the Duke database (9), which
stimated an ICD placement cost of $32,914, or $35,000
fter converting to 2004 dollars. For ongoing costs of ICD
herapy, ICD generator replacements ($18,000) would oc-
ur every six years, and patients with lead fractures and lead
ocket infections would incur additional inpatient costs
25,28,32). Patients presenting with SCD not saved by ICD
herapy incurred further costs if resuscitation attempts were
ade (probability  10%), with the cost dependent upon
hether the patient survived until discharge (33–35). Fi-
ally, those who survived until discharge after a resuscitated
CD event incurred different annual health care costs
epending upon their level of impairment (7,33,36). All cost
stimates were standardized to 2004 U.S. dollars by using
he Consumer Price Index for all urban consumers (37) and
ere analyzed across their range of estimates in sensitivity
nalysis.
tilities. Quality-of-life adjustments for utility estimates
ere derived from published data and also discounted at 3%
er year. We made a conservative assumption that ICD
mplantation did not modify the utility of MADIT-II–
ligible patients relative to medical therapy and assigned a
aseline utility of 0.88 to all patients in the cohort
31,38,39). Health utilities for patients surviving a SCD
ere estimated from either the SCD or stroke literature for
arying degrees of impairment (40–44).
ensitivity analysis. One-way sensitivity analysis was per-
ormed for each model variable across its range of estimates
rom Table 1. Because varying the mortality hazard ratio for
TWA testing would invariably change the baseline mor-
ality rate, the effect of this variable on incremental cost-
ffectiveness was examined in two-way sensitivity analyses
ith the annual mortality rate. Moreover, those variables
able 2. Incremental Cost-Effectiveness Ratios in Base-Case Est
Lifetime Cost Life-Years
lacing ICDs in all $157,993 8.2
isk stratify with MTWA $136,449 8.0
edical management $80,782 6.7
ncremental cost-effectiveness ratios (ICERs) comparing the three strategies for MAD
herapy has an ICER comparable to that of hemodialysis ($50,000 per QALY) and
isk stratification strategy would not be considered cost-effective. All ICER results ar
CER calculations are due to round-off error.
QALY  quality-adjusted life-year; other abbreviations as in Table 1.ith the highest uncertainty in the one-way analysis were turther examined in two-way sensitivity analyses. Finally,
ultivariable sensitivity analysis was conducted using
0,000 second-order Monte Carlo simulations. For each
imulation, the distribution of the ranges of every model
ariable is randomly sampled (to account for the uncertain-
ies of each model variable) in order to generate an incre-
ental cost-effectiveness ratio (ICER) estimate. This anal-
sis assesses the precision of the primary cost-effectiveness
stimates from the Markov model by providing a distribu-
ion of likely ICER estimates with the 10,000 simulations.
e assumed normal distributions for most variables, with the
ensitivity analysis covering four standard deviations for the
ariable’s estimate range. For cost and probabilities that were
kewed, we assigned log-normal distributions for the analysis.
ESULTS
able 2 shows model predictions for the three treatment
trategies. A strategy involving ICD therapy for all MADIT-
I–eligible patients was most effective (7.25 QALYs), fol-
owed by risk stratification with MTWA (7.00 QALYs) and
edical therapy (5.86 QALYs). Similarly, ICD therapy for
ll patients was the most expensive ($157,993), followed by
isk stratification with MTWA ($136,449) and medical
herapy ($80,782). When a risk-stratification strategy with
TWA is compared to the base-case strategy of medical
herapy, 1.14 QALYs are gained at an incremental cost of
55,667, representing an ICER of $48,800 per QALY
ained. A strategy that implants ICDs in all yields a higher
CER of $55,800/QALY compared with medical therapy.
inally, compared to a MTWA risk-stratification strategy,
n ICD-for-all strategy gained an additional 0.24 QALYs
t an incremental cost of $21,544, yielding an ICER of
88,700/QALY. This suggests that 83% of the total poten-
ial benefit of ICDs can be achieved by implanting ICDs in
he 67% of patients who test MTWA non-negative (1.14
ncremental QALYs [risk stratification with MTWA]/1.38
ncremental QALYs [ICDs-for-all]).
ne-way sensitivity analysis. The results of one-way sen-
itivity analyses for variables with the highest sensitivity are
hown in Table 3.
OMPARISON OF MTWA RISK STRATIFICATION WITH MED-
CAL THERAPY. Compared to medical therapy, results of
ne-way sensitivity analyses were relatively insensitive, with
s
Ys
ICER
(Relative to Medical Therapy)
ICER
(Relative to MTWA)
46 $55,800/QALY $88,700/QALY
04 $48,800/QALY Base-case
63 Base-case —
eligible patients are shown. AMTWA risk stratification strategy compared to medical
likely be considered cost-effective. An ICD-for-all strategy compared to a MTWA
sured in 2004 U.S. dollars and are rounded off to the nearest $100. Discrepancies inimate
QAL
7.2
7.0
5.8
IT-II
would
e meahe upper ICER estimate range consistently below $62,000
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atio inherently increases the baseline annual mortality rate,
his variable was further explored as a two-way sensitivity
nalysis (Fig. 2). At the base-case annual mortality rate of
0.1%, threshold analysis found that the MTWA hazard
igure 2. Effect of the microvolt T-wave alternans (MTWA) hazard ratio
o medical therapy. As varying the MTWA hazard ratio changes the underly
s performed as a two-way sensitivity analysis. Base-case estimates are fo
able 3. Summary Table of One- and Two-Way Sensitivity Ana
Variables
MTWA S
Medica
TWA mortality hazard ratio (1.0–5.0) $52,200
CD proportion of overall mortality (40%–60%) $55,300
CD reduction by ICD (50%–70%) $56,100
ost of ICD ($30,000–$50,000) $45,700
aseline annual mortality (7.0%–13.0%) $58,100
ost of annual care ($7,000–$20,000) $44,700
TWA negative screen rate (10%–50%) $51,200
aseline utility for well health (0.7–1.0) $61,500
ead infection risk (0.5%–2.0%) $47,400
iscount rate (0%–5%) $43,100
Variables
TWA mortality hazard ratio  SCD proportion
TWA mortality hazard ratio  ICD efficacy
TWA mortality hazard ratio  ICD cost
CD proportion  ICD efficacy
CD proportion  ICD cost
CD efficacy  ICD cost
ariables with the greatest influence on incremental cost-effectiveness ratios when eval
o single variable significantly influenced the incremental cost-effectiveness ratio com
everal variables were highly influential when an ICD-for-all strategy was compared
wo-way sensitivity analysis, using the upper and lower limits of each variable’s range
Abbreviations as in Tables 1 and 2.ncremental cost-effectiveness of a risk stratification strategy with MTWA com
atio or the annual mortality rate increases. ICER  incremental cost-effectivenatio would need to be 1.8 to yield an ICER of
$50,000 per QALY. As seen in Figure 2, the ICER for
MTWA risk-stratification strategy compared to medi-
al therapy decreases with a higher baseline annual
ortality rate or a higher MTWA mortality hazard ratio.
st-effectiveness when comparing a risk stratification strategy with MTWA
aseline annual mortality rate, the effect of this variable on cost-effectiveness
nnual mortality rate of 10.1% and a MTWA hazard ratio of 2.35. The
One-Way Sensitivity Analysis
ing vs.
rapy
ICDs For All vs.
Medical Therapy
ICDs for All vs.
MTWA Screening
7,800 N/A $61,000 to $149,500
4,600 $64,300 to $50,500 $111,400 to $76,400
5,100 $64,900 to $51,200 $107,800 to $79,700
1,200 $52,200 to $70,200 $82,800 to $112,300
4,800 $67,300 to $50,600 $116,400 to $75,400
9,600 $51,700 to $66,600 $84,600 to $99,400
6,200 N/A $91,700 to $80,900
2,900 $70,300 to $49,100 $111,500 to $78,100
5,600 $54,000 to $59,400 $85,100 to $96,000
3,100 $48,800 to $61,100 $74,700 to $99,600
Two-Way Sensitivity Analysis
ICDs for All vs. MTWA Screening
$55,200 to $190,800
$55,200 to $188,300
$56,800 to $188,900
$68,900 to $136,200
$71,600 to $134,400
$74,500 to $137,500
across the range of estimates from Table 1 are shown for one-way sensitivity analyses.
a MTWA risk stratification strategy with the base case of medical therapy. However,
a MTWA risk stratification strategy, and these variables are further examined with
mates. Dollar amounts are in 2004 US dollars and are per quality-adjusted life-year.on co
ing b
r an alyses
creen
l The
to $4
to $4
to $4
to $6
to $4
to $5
to $4
to $4
to $5
to $5
uated
paring
with
of estipared to medical therapy becomes more favorable as the MTWA hazard
ess ratio; QALY  quality-adjusted life-year.
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Cost-Effectiveness of MTWA Screening July 4, 2006:112–21OMPARISONOF ICD-FOR-ALL STRATEGYWITHMTWARISK
TRATIFICATION. When an ICD-for-all strategy is com-
ared with a MTWA risk-stratification strategy, results were
ost sensitive to the mortality hazard ratio forMTWA testing
Table 3). As before, the impact of this variable on incremental
ost-effectiveness is best appreciated as a two-way sensitivity
nalysis with annual mortality (Fig. 3). At the base-case
ortality hazard ratio of 2.35 and annual mortality risk of
0.1%, the ICER is $88,700 per QALY. The ICER
ecreases with a higher annual mortality rate or a less
redictive MTWA test. However, even when the MTWA
creening test is non-discriminating (hazard ratio  1), the
nnual mortality rate would need to be 15% to yield an
CER $50,000 per QALY.
Other variables with significant impact in the one-way
ensitivity analyses included the MTWA negative screen
ate, patient risk for arrhythmic death, the cost and efficacy
f ICD therapy, baseline annual mortality rate, baseline
tility for health, and discount rate used. Finally, when we
imited the mortality benefit of MTWA screening to only
he first two years, an ICD-for-all strategy yielded an ICER
f $76,500 per QALY.
WO-WAY SENSITIVITY ANALYSIS. Because no single vari-
ble exerted significant impact in the one-way sensitivity
nalysis when compared with a medical therapy strategy as
he base case, there remained little variability in two-way
ensitivity analyses, with none of the upper-range estimates
or the MTWA risk-stratification strategy exceeding
100,000 per QALY gained (results not shown). In con-
rast, when an ICD-for-all strategy was compared with a
TWA risk-stratification strategy, several variables showed
igure 3. Effect of the MTWA hazard ratio on cost-effectiveness when co
ncremental cost-effectiveness of an ICD-for-all strategy compared to a r
ortality rate increases or as the MTWA hazard ratio decreases. Abbreviigh sensitivity in two-way sensitivity analyses (Table 3). bowever, in no instance did the ICER of the ICD-for-all
trategy compared to a MTWA risk-stratification strategy
all below $55,000 per QALY gained.
ULTIVARIABLE SENSITIVITY ANALYSIS. Monte Carlo sim-
lations demonstrated that the ICER for the MTWA
isk-stratification strategy compared to medical therapy had
100% probability of being $100,000 per QALY gained,
nd a 55% probability of being$50,000 per QALY gained
n the MADIT-II population (Fig. 4). The ICER for an
CD-for-all strategy compared with MTWA risk stratifi-
ation had a 26% probability of being $100,000 per
ALY gained and a 0% probability of being $50,000 per
ALY gained (Fig. 5).
ISCUSSION
lthough ICDs have been found to be efficacious in patients
ith ischemic cardiomyopathy, the cost-effectiveness and
ost-affordability of these life-saving devices over a lifetime
emains less certain. Our study found that when MADIT-
I–eligible patients are first risk-stratified with MTWA
esting, the incremental cost-effectiveness of ICD therapy
ompared with medical therapy was comparable to that of
emodialysis ($50,000 per QALY gained), an oft-cited
enchmark for cost-effectiveness (45). When ICD therapy
as provided to all MADIT-II–eligible patients, compared
ith medical therapy alone, incremental cost-effectiveness
ncreased moderately, suggesting that its proper comparator
ould be the MTWA risk-stratification strategy (14).
ompared to a MTWA risk-stratification strategy, provid-
ng ICDs for all patients generated only a small amount of
ng an ICD-for-all strategy with a MTWA risk stratification strategy. The
ratification strategy with MTWA becomes more favorable as the annual
as in Figures 1 and 2.mpari
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ffectiveness thresholds (14).
Sensitivity analyses showed that no model variable exerted
ignificant influence when a MTWA risk-stratification strat-
gy was compared to a medical therapy strategy, implying that
he incremental cost-effectiveness estimates are likely to be in
he $42,000 to $62,000 per QALY range. When an ICD-for-
ll strategy was compared with a MTWA risk-stratification
trategy, one-way, two-way, and multivariable sensitivity
nalyses showed that it was unlikely to be cost-effective.
inally, even in the unlikely scenario in which the mortality
igure 4. Estimated distribution of the incremental cost-effectiveness ra
ADIT-II–eligible population. Data were obtained by performing 1
50,000/QALY in 5,459 (54.6%) of the simulations, whereas none o
bbreviations as in Figures 1 and 2.
igure 5. Estimated distribution of the incremental cost-effectiveness ratio
ADIT-II–eligible population. Data were obtained by performing
100,000/QALY in 2,594 (25.9%) of all simulations, whereas no simulations
igures 1 and 2.enefit of MTWA screening was limited to only the first
wo years (i.e., time frame of the prospective cohort studies
or MTWA), an ICD-for-all strategy would probably still
ot be considered cost-effective (ICER: $76,500 per
ALY).
Despite the recent decision by CMS to expand defibril-
ator coverage to MADIT-II–eligible patients irrespective
f QRS duration, ongoing concerns on the cost implications
f this decision persist. One recent study estimates that
2,000 new MADIT-II patients in the U.S. were eligible
or defibrillator implantation in the year 2000 (9). Our
f risk stratification with MTWA testing versus medical therapy in the
Monte Carlo simulations. The cost-effectiveness ratio was less than
simulations yielded cost-effectiveness ratios above $100,000/QALY.
ICD-for-all strategy versus risk stratification with MTWA testing in the
0 Monte Carlo simulations. The cost-effectiveness ratio was abovetio o
0,000of an
10,00gave cost-effectiveness ratios below $50,000/QALY. Abbreviations as in
m
b
m
I
p
i
s
s
c
t
Q
p
c
i
$
l
c
T
w
(
a
s
t
e
m
c
n
Q
g
f
r
t
i
a
l
I
s
M
l

s
y
i
a
s
y
I
b
c
t
c
I
a
b
P
b
s
S
w
b
g
a
S
l
f
s
r
u
i
p
i
p
t
e
a
M
b
c
u
l
a
o
C
M
M
m
e
w
c
a
R
A
R
u
R
120 Chan et al. JACC Vol. 48, No. 1, 2006
Cost-Effectiveness of MTWA Screening July 4, 2006:112–21odel suggests that the lifetime incremental cost of defi-
rillator therapy in an ICD-for-all strategy compared to
edical therapy is $77,200 per patient (lifetime cost for
CD patient  $157,993; lifetime cost for medical therapy
atient  $80,782 from Table 2), which is similar to the
ncremental lifetime cost of $90,800 determined in another
tudy (9), in order to generate 1.38 QALY per patient. This
uggests that an ICD-for-all strategy would, over a lifetime,
ost an incremental $2.47 billion ($77,200  32,000 pa-
ients) and save an incremental 44,160 QALYs (1.38
ALY  32,000 patients) for 100% penetration of this
olicy for each year of patients who meet MADIT-II
riteria. If an MTWA risk stratification strategy was used
nstead, the average incremental lifetime cost would be
55,700 to gain 1.14 QALYs per patient, or an incremental
ifetime cost of $1.78 billion to save 36,480 QALYs by
overing all newly eligible MADIT-II patients annually.
his suggests that a MTWA risk stratification strategy
ould save $690 million (28%) but lose 7,680 QALYs
17%) to cover all newly eligible MADIT-II patients
nnually compared to an ICD-for-all strategy.
Our study demonstrates that a MTWA risk stratification
trategy is a more cost-effective approach to ICD implan-
ation than an ICD-for-all strategy in the MADIT-II–
ligible population. Until more effective risk stratification
odels are developed, this suggests that ICDs may be
onsidered cost-effective in those who test MTWA non-
egative at a cost-effectiveness threshold of $50,000 per
ALY. For those who test MTWA negative, however,
iven their lower sudden cardiac death risk and the potential
or ICD complications, ICDs may not be cost-effective. It
emains unclear whether annual screening with MTWA
esting in those who screen MTWA negative may further
ncrease the negative predictive power of MTWA testing
nd therefore be an alternative option for such patients.
We made conservative assumptions for model inputs that
ikely yielded a more favorable ICER when comparing an
CD-for-all strategy with a MTWA risk-stratification
trategy. We used a mortality hazard ratio of 2.35 for
TWA non-negative versus negative patients from the
argest study involving MADIT-II type patients to date (n
537) (13). A higher mortality HR of 4.7, as seen in the
tudy by Bloomfield et al. (12) (n  177), would have
ielded an ICER of $142,400 per QALY (Fig. 3). However,
n that smaller study, the mortality HR derived was not
ge-adjusted and reflected a younger population than that
een in the MADIT-II trial population (mean age  65
ears). Nevertheless, it is likely that the ICER for an
CD-for-all versus a MTWA risk stratification strategy may
e higher than $88,000 per QALY, especially as our model
onservatively assumed a fixed survival benefit with ICD
herapy over patient lifetime, similar annual medical therapy
osts for the ICD and non-ICD groups, and low rates of
CD complications, all of which would favor the ICD-for-
ll strategy.Our study had several limitations. To date, there have
een no published randomized clinical trials with MTWA.
rospective cohort studies may have unmeasured selection
ias, although the consistent robust findings across different
tudies using MTWA to identify patients at high risk for
CD would suggest that, even if such bias existed, there
ould likely remain significant differences in SCD risk
etween the MTWA negative and non-negative patient
roups. Decision-analytical models also make simplifying
ssumptions, and we extrapolated the rates for overall and
CD mortality derived from the literature for patient
ifetime. These rates may not be linear beyond the study’s
ollow-up periods or may be outside the ranges used for our
ensitivity analyses. It was assumed that patients who
eceived ICDs would not have a change in health state
tility, although some might argue that an ICD could either
ncrease or decrease (from frequent inappropriate shocks) a
atient’s health state utility, which would decrease or
ncrease, respectively, the cost-effectiveness estimates com-
aring a MTWA risk stratification strategy with medical
herapy. Our study’s cost-effectiveness estimates were gen-
rated for a hypothetical 65-year-old cohort and may not be
pplicable to older or younger MADIT-II–eligible patients.
oreover, these results reflect mean ICERs for the cohort
ut do not provide patient-specific ICERs based on one’s
ovariate distribution. Finally, we did not model potential
ses of biventricular pacers with defibrillators in this popu-
ation with left ventricular dysfunction, as this would require
more complex model with additional assumptions that are
utside the scope of the present study.
onclusions. Implantable cardioverter-defibrillators in
ADIT-II–eligible patients who are risk stratified by
TWA testing are costly but likely cost-effective. Imple-
enting a policy of ICD placement in all MADIT-II–
ligible patients compared to a risk stratification strategy
ith MTWA, however, is not likely to be considered
ost-effective, with one-third of patients deriving little
dditional benefit at great expense.
eprint requests and correspondence: Dr. Paul S. Chan, VA
nn Arbor Healthcare System, Cardiology (111-A), 2215 Fuller
oad, Ann Arbor, Michigan 48105. E-mail: paulchan@
mich.edu.
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